Compare SGHC & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | COGT |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.5B |
| IPO Year | N/A | 2018 |
| Metric | SGHC | COGT |
|---|---|---|
| Price | $9.35 | $35.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 14 |
| Target Price | $17.67 | ★ $32.08 |
| AVG Volume (30 Days) | 2.1M | ★ 2.4M |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ 4925.62 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $2,342,912,011.00 | N/A |
| Revenue This Year | $28.42 | N/A |
| Revenue Next Year | $10.86 | N/A |
| P/E Ratio | $20.91 | ★ N/A |
| Revenue Growth | ★ 34.94 | N/A |
| 52 Week Low | $5.59 | $3.72 |
| 52 Week High | $14.38 | $43.73 |
| Indicator | SGHC | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 32.02 | 44.23 |
| Support Level | $9.58 | $36.01 |
| Resistance Level | $10.40 | $39.65 |
| Average True Range (ATR) | 0.43 | 1.91 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 9.30 | 27.30 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.